BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36159813)

  • 1. Non-coding RNA-mediated high expression of
    Chen K; Gong S; Fang X; Li Q; Ye M; Li J; Huang S; Zhao Y; Liu N; Li Y; Ma J
    Front Immunol; 2022; 13():920136. PubMed ID: 36159813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
    Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
    Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a competing endogenous RNA network in head and neck squamous cell carcinoma by pan-cancer analysis.
    Zheng D; Luo S; Wang S; Huang J; Zhou Y; Su L; Chen Z; Wang S; He W
    Transl Cancer Res; 2022 Sep; 11(9):3050-3063. PubMed ID: 36237258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
    Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
    Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
    Chen Y
    Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
    Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
    Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
    Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
    PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
    Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
    Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
    Li Y; Liu H
    Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spermine synthase (
    Pan X; Xue L; Sun Y
    Ann Transl Med; 2022 Nov; 10(22):1213. PubMed ID: 36544695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
    Huang C; Liu J
    Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
    Liu S; Wang S; Wang Z
    BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.